June 5, 2014 | Teva Pharmaceutical Industries acquired Labrys Biologics for up to $825 million, according to Globes. The leading Israeli pharmaceutical company reportedly payed Labrys $200 million in cash upfront and will pay up to $625 million in contingent payments following launch.
Labrys Biologics is a private biotechnological company focused on treatments for chronic and episodic migraine headaches. The acquisition of the company aids in Teva’s goal of becoming a world leader in pain by the year 2020.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments